Centessa Pharmaceuticals plc (NASDAQ: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference in New York. A fireside chat is scheduled for Wednesday, September 4 at 1:05 PM ET.
The live audio webcast of this event, as well as an archived recording, will be available under the “Events and Publications” tab on the investor relations section of the Centessa Pharmaceuticals website at https://investors.centessa.com/events-presentations.
Centessa Pharmaceuticals is a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients. Our most advanced programs include a hemophilia program, an orexin agonist program for the treatment of narcolepsy and other sleep-wake disorders and an immuno-oncology program focused on our LockBody technology platform. “We operate,” this morning’s news release stated, “with the conviction that each one of our programs has the potential to change the current treatment paradigm and establish a new standard of care.”
CNTA shares acquired 14 cents, or 1.2%, to $12.16.
